Academic Journal
Q1Journal of Clinical Oncology
About Journal of Clinical Oncology
Journal of Clinical Oncology is a scholarly journal published by Lippincott Williams and Wilkins. SCImago 2025 places it in Q1 with an SJR of 4.648 and an H-index of 666.
Its listed coverage is 1983-2026 and its research categories include Cancer Research (Q1); Medicine (miscellaneous) (Q1); Oncology (Q1). The 2025 dataset reports 1245 documents and 33240 citations across the latest three-year reporting window.
The Journal of Clinical Oncology (JCO) is one of the most prestigious peer-reviewed medical journals dedicated to cancer research and treatment. Published by the American Society of Clinical Oncology (ASCO), JCO serves as a vital resource for oncologists, researchers, and healthcare professionals worldwide. The journal covers cutting-edge clinical research, innovative treatment approaches, and significant advancements in oncology.
About the Journal of Clinical Oncology
Since its establishment in 1983, the Journal of Clinical Oncology has been at the forefront of oncology research, providing high-impact articles that shape clinical practice. With a strong reputation for scientific integrity and rigorous peer review, JCO publishes original research, reviews, editorials, and clinical guidelines that contribute to improving cancer diagnosis, treatment, and patient care.Key Features of JCO
1. High-Impact Research
JCO publishes groundbreaking studies that influence oncology care, including clinical trials, targeted therapies, immunotherapies, and precision medicine. The journal’s research articles provide valuable insights for oncologists and researchers striving to enhance cancer treatment.2. Diverse Oncology Topics
The journal covers a wide range of topics, including:- Breast cancer, lung cancer, prostate cancer, and other malignancies
- Hematologic oncology
- Immunotherapy and targeted treatments
- Radiation oncology and surgical oncology
- Supportive care and palliative medicine
- Epidemiology and cancer prevention
3. Clinical Guidelines and Expert Opinions
JCO publishes expert-reviewed guidelines and recommendations that help oncologists make informed decisions regarding patient care and treatment strategies.4. Specialized Sections
The journal features dedicated sections such as JCO Global Oncology, JCO Clinical Cancer Informatics, and JCO Precision Oncology, which focus on different aspects of cancer research and treatment.5. Accessibility and Open Access
While JCO is primarily a subscription-based journal, selected articles are available as open-access content. This ensures that crucial oncology research is accessible to a broader audience, including healthcare providers and researchers in developing countries.Why JCO Matters for the Oncology Community
Advancing Cancer Treatment
JCO plays a crucial role in advancing cancer treatment by disseminating the latest clinical research findings. Its articles influence the development of new drugs, innovative therapies, and personalized treatment approaches.Evidence-Based Decision-Making
Oncologists and healthcare providers rely on JCO’s research and clinical guidelines to make informed treatment decisions, ultimately improving patient outcomes.Global Impact
With contributions from leading oncologists and researchers worldwide, JCO fosters collaboration and knowledge-sharing in the fight against cancer.Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The Journal of Clinical Oncology (JCO) is a leading peer-reviewed medical journal dedicated to advancing the field of clinical oncology. Published by the American Society of Clinical Oncology (ASCO), the journal serves as a vital resource for oncologists, researchers, and healthcare professionals worldwide. It provides cutting-edge research, evidence-based practices, and innovative treatment strategies aimed at improving cancer care and patient outcomes.
Key Areas of Focus
The Journal of Clinical Oncology covers a broad range of topics within the field of oncology, including but not limited to:- Clinical Research and Trials – JCO publishes high-quality clinical trials that shape the future of cancer treatment. These studies provide insights into new therapies, drug efficacy, and patient response rates.
- Cancer Prevention and Early Detection – The journal emphasizes strategies for cancer prevention, risk assessment, and early detection methods that can improve survival rates.
- Personalized and Precision Medicine – JCO explores the role of genomics, biomarkers, and targeted therapies in developing individualized treatment plans.
- Immunotherapy and Targeted Therapies – With the growing significance of immunotherapy in cancer treatment, JCO highlights research on immune checkpoint inhibitors, monoclonal antibodies, and emerging targeted drug therapies.
- Palliative and Supportive Care – JCO addresses ways to enhance the quality of life for cancer patients, including pain management, psychological support, and survivorship care.
- Oncology Guidelines and Best Practices – The journal provides updated clinical practice guidelines that help oncologists make informed decisions regarding patient care.
- Health Disparities and Global Oncology – JCO is committed to addressing healthcare disparities and promoting equitable cancer care worldwide through research and policy discussions.
Types of Publications
JCO features various types of content, including:- Original Research Articles – Peer-reviewed studies on new oncology treatments and methodologies.
- Review Articles – Comprehensive overviews of specific cancer-related topics.
- Editorials and Commentaries – Expert opinions and discussions on recent advancements in oncology.
- Clinical Practice Guidelines – Evidence-based recommendations for oncologists.
- Case Reports and Letters – Unique clinical cases and professional correspondence discussing emerging trends in oncology.
Impact and Readership
The Journal of Clinical Oncology has a high impact factor, making it a trusted source of information for the global oncology community. It reaches a diverse audience of oncologists, researchers, healthcare policymakers, and medical professionals interested in the latest advancements in cancer care. With its rigorous peer-review process and commitment to scientific excellence, JCO continues to drive innovation in oncology, improving patient outcomes and shaping the future of cancer treatment.Recent Research Articles
Latest publications matched automatically by ISSN.
Sustaining High Reliability Amid Artificial Intelligence Adoption in Oncology
Shawn Stapleton, Renu Sara Nargund, Caroline Chung
2026-09-10 · DOI: 10.1200/jco-26-00253He Was Always There
Vangipuram Sai Shreya
2026-09-10 · DOI: 10.1200/jco-26-00540Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
Ting Li, Teng Zhou, Biyun Wang, Zhonghua Tao et al.
2026-09-10 · DOI: 10.1200/jco-25-02021Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer
Audrey Beaufils, Julien De Martino, Xiaofeng Jiang, Théau Blanchard et al.
2026-09-10 · DOI: 10.1200/jco-26-00327Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira et al.
2026-09-10 · DOI: 10.1200/jco-26-01931COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma
Antoni Ribas, Caroline Robert, Dirk Schadendorf, Georgina V. Long et al.
2026-09-10 · DOI: 10.1200/jco-26-00528Role of Risk-Reducing Bilateral Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers
Nicholas S. Rau
2026-09-10 · DOI: 10.1200/jco-26-00519Oncology Drug Development: Challenges of Increasingly Available Therapies
Sundeep Agrawal, Richard Pazdur
2026-09-10 · DOI: 10.1200/jco-25-02840Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
David A. Sallman, Guillermo Garcia-Manero, Naval Daver, Camille N. Abboud et al.
2026-09-10 · DOI: 10.1200/jco-25-00617Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy
Nadine M. Tung, Tianyu Li, Judy E. Garber
2026-09-10 · DOI: 10.1200/jco-26-00940Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy
Jinyin Yan, Wei Xiong, Haifeng Cai
2026-09-10 · DOI: 10.1200/jco-26-00539Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study
Adnan Khattak, Matteo S. Carlino, Tarek Meniawy, George Ansstas et al.
2026-09-10 · DOI: 10.1200/jco-26-00835Reply to: Role of Risk-Reducing Bilateral Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers
Ashu Gandhi, Sacha J. Howell, D. Gareth Evans
2026-09-10 · DOI: 10.1200/jco-26-01190Should Artificial Intelligence Direct Systemic Therapy Decisions in Pancreatic Cancer?
Gabriel A. Brooks, Raghav Sundar
2026-09-10 · DOI: 10.1200/jco-26-00303Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Ashutosh D. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis et al.
2026-09-10 · DOI: 10.1200/jco-26-01665Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2
Sonam Puri, Nofisat Ismaila, Ibrahim Hanna Azar, Janet Freeman-Daily et al.
2026-09-10 · DOI: 10.1200/jco-26-01479Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer
Andrew E. Hendifar, Viswesh Krishna, Vrishab Krishna, Haochen Zhang et al.
2026-09-10 · DOI: 10.1200/jco-25-02199Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study
Andréa Witz, Thierry Conroy, Aurélien Lambert, Julia Salleron et al.
2026-09-10 · DOI: 10.1200/jco-25-02508International Breast Cancer Trials and Optimal Sequence of Treatment
Uri Bender, Karine Ronan, Eitan Amir
2026-09-04 · DOI: 10.1200/jco-26-01228Breast Cancer Risk Assessment Has a Data Integration Problem: Can Artificial Intelligence Solve It?
Payal D. Shah, Ravi B. Parikh
2026-09-04 · DOI: 10.1200/jco-26-01598Reviews
Community Reviews
Version History
April 14, 2025 at 12:12 pm
March 24, 2025